Last updated: February 24, 2026
What Is the Drug Associated With NDC 00037-2001?
NDC 00037-2001 corresponds to Humira (adalimumab), a monoclonal antibody used primarily to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is among the highest-value biologics in the global pharmaceutical market.
Market Overview
Market Size and Growth Dynamics
Humira's global sales peaked around $20.3 billion in 2021, driven by broad indications, high disease prevalence, and established clinical efficacy. Despite a patent expiration threat from biosimilars, its sales sustained significant revenue due to its widespread use and physician brand loyalty.
Competitive Landscape
Biosimilar entries began in selected markets in 2019, with aggressive pricing strategies targeting Humira. Major competitors include:
- Amgen's Amjevita (adalimumab-atto)
- Sandoz's Hyrimoz (adalimumab-adazi)
- Samsung's Imraldi
- Pfizer's Cyltezo
These biosimilars are launching at reduced prices, typically 15-35% lower than Humira.
Regulatory and Patent Environment
U.S. patent protection for Humira expired in Jan 2023, allowing biosimilars to enter the market. However, patent litigations and exclusive marketing agreements have delayed full biosimilar uptake in the U.S. until at least 2024.
In the EU, biosimilars entered earlier, leading to approximately 40-50% price reductions compared to the original.
Key Market Factors
- Pricing elasticity: Price reductions of 20-30% in the U.S. are associated with a 10-25% volume increase.
- Formulations: Multiple dosage forms (pen, syringe, auto-injector) influence patient and provider preferences, affecting market penetration.
- Insurance coverage: Reimbursement policies impact access and sales volume, particularly in the U.S.
Price Projections
Historical Pricing Trends
- Humira (U.S.): Average wholesale price (AWP) around $2,600 per month per patient (before insurance). Post-2020, prices remained relatively stable prior to biosimilar entry.
- Biosimilar Pricing: Biosimilars are priced 20-35% lower, translating to about $1,700–$2,000 per month.
Near-Term Price Expectations (2023–2025)
| Scenario |
Expected Wholesale Price (per month) |
Notes |
| Pre-biosimilar (2023) |
$2,600 |
Humira maintains premium price, limited biosimilar impact. |
| Post-biosimilar (mid-2024) |
$1,800–$2,000 |
Biosimilar uptake accelerates, prices decline 22-30%. |
| Long-term (2025+) |
$1,500–$1,800 |
Market stabilizes; continued biosimilar penetration. |
Revenue Impact
Total revenue for Humira in the U.S. will decline correspondingly with price reductions and volume increases. Estimated:
- 2023: $15–18 billion (assuming some biosimilar presence)
- 2024: $10–12 billion (biosimilar volume growth)
- 2025: $8–10 billion
International markets' prices vary, often lower than U.S. levels, with expected reductions of 10-20% over the next two years.
Strategic Considerations
- Pharma companies might adjust prices in response to biosimilar competition.
- Emphasis on differentiating factors such as formulation, delivery method, and patient support programs becomes critical.
- Payor negotiations could further influence net prices.
Key Takeaways
- Humira retains high sales but faces imminent competition from biosimilars from 2024 onward.
- U.S. prices are expected to decline by approximately 20-30%, with biosimilar volumes compensating partially.
- International markets are experiencing earlier biosimilar adoption with significant price reductions.
- Margins will compress as biosimilar competition intensifies, pressuring revenue growth.
FAQs
Q1. How soon will biosimilars impact Humira's U.S. sales?
Biosimilar launches are expected to significantly affect U.S. market share from mid-2024 onward, contingent on patent litigation outcomes.
Q2. How do biosimilar prices compare internationally?
European biosimilars typically sell at a 40-50% discount to the original, with reductions of about 20-35% in other markets.
Q3. What factors could delay biosimilar uptake?
Patent litigations, market exclusivity agreements, rebate strategies, and prescribing habits can slow biosimilar penetration.
Q4. How does formulation diversity influence market share?
Different delivery systems can attract specific patient populations, potentially extending Humira's market share even post-biosimilar entry.
Q5. What R&D strategies might Pfizer or rivals pursue?
Focus on next-generation biologics, improved formulations, or novel indications to sustain revenues amid biosimilar competition.
References
[1] IQVIA. (2022). Pharmaceutical Market Reports.
[2] Evaluate Pharma. (2022). Global Prescription Drug Market Outlook.
[3] U.S. Food & Drug Administration. (2022). Biosimilar and Interchangeable Product Biosimilar Guidance.
[4] European Medicines Agency. (2022). Biosimilars Market Data.
